Elizabeth Folkerd

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Gerhardt Attard, Alison Reid, Timothy A. Yap et al. · Journal of Clinical Oncology · 2008 · 896 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men

Kay‐Tee Khaw, Mitch Dowsett, Elizabeth Folkerd et al. · Circulation · 2007 · 741 citations

Medicine, Endocrinology, Epidemiology +16

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Gerhardt Attard, Alison Reid, Roger A’Hern et al. · Journal of Clinical Oncology · 2009 · 603 citations · Full text

Medicine, Oncology, Pharmacology +17

Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women

Alison M. Dunning, Mitch Dowsett, Catherine S. Healey et al. · JNCI Journal of the National Cancer Institute · 2004 · 343 citations · Full text

Medicine, Endocrinology, Genetics +14

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Stephen Johnston, Lucy Kilburn, David Dodwell et al. · The Lancet Oncology · 2013 · 275 citations · Full text

Medicine, Oncology, Pharmacotherapy +16